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Several single-center studies have conﬁrmed the usability of cerebrospinal ﬂuid (CSF) biomarkers for the diagnosis of Alzheimer’s
disease (AD), even in early disease stages. Large scale multicenter studies have principally conﬁrmed this, although such studies
have also indicated the presence of signiﬁcant intercenter and interlaboratory variations in biomarker measurements. Such
variations may hamper the development of biomarkers and their introduction into clinical routine practice. Recently a quality
control program run by the Alzheimer’s Association was started in order to harmonize procedures of laboratories world-wide.
This program provides both standardized guide lines and external control CSF samples, and will allow longitudinal evaluation of
laboratory performance.
1.Introduction
The ongoing development of disease modifying treatment
for Alzheimer’s disease (AD) puts pressure on researchers
to develop reliable biomarkers for diagnosis, disease pro-
gression and monitoring of treatment eﬀect. For these
purposes, the most promising biomarkers are imaging and
cerebrospinal ﬂuid (CSF) markers [1–3]. The core CSF
biomarkers are β-amyoid42 (Aβ42), total-tau (T-tau), and
phosphorylated tau (P-tau), where the most frequently used
P-tau isoforms are tau phosphorylated at the threonine
amino acid residues 181 or 231 [1]. CSF Aβ42, T-tau and P-
tau correspond to the principal neuropathological elements
of AD: extracellular amyloid plaques, axonal degeneration,
and intraneuronal tangles. Indeed, autopsy studies and
imaging studies have revealed that CSF biomarker concen-
trations correspond well to brain alterations [4–7]. The
accessibility of CSF for analysis and the low cost of CSF
biomarkermeasurementsfavortheirusagefordetection,and
monitoring of pathological processes in the brain. Several
studies have shown that AD patients have decreased CSF
Aβ42 and increased T-tau and P-tau compared with healthy
controls [8]. Noteworthy, T-tau and P-tau correlate in AD
patients and controls but not in several other neurological
diseases. T-tau is increased in several neurodegenerative
conditions and is a sensitive but unspeciﬁc AD biomarker
[9]. P-tau, on the other hand, may add speciﬁcity for AD in
dementia investigations [10].
2. CSFBiomarkers inEarlyDiagnosis
Brain alterations are likely to start long before onset of
clinical dementia. Thus, biomarkers that detect changes in
the brain are likely altered at a clinically early stage. It has
been proposed that biomarker alterations occur dynamically
during the disease process, with Aβ and Tau markers
changed ﬁrst, followed by distortion of brain structure,
decline of memory and ultimately clinical dysfunction [11].
Supporting the use of CSF biomarkers for early diagno-
sis, decreased Aβ42 and increased T-tau and P-tau are
seen in patients with mild cognitive impairment (MCI)
later diagnosed with AD. In a well-controlled monocenter
study, Hansson and coworkers followed 137 MCI patients
for 4–6 years, during which 57 patients were diagnosed
with AD. The CSF biomarkers sampled at baseline had2 International Journal of Alzheimer’s Disease
a sensitivity of 95% and a speciﬁcity 83% for incipient
AD [12]. Since clinical AD diagnosis lacks some accuracy
versus autopsy conﬁrmation, it is probably not possible
to achieve a signiﬁcantly higher diagnostic accuracy for
biomarkers towards clinical diagnosis. In line with this,
consensus reports recommend that AD biomarkers should
have at least 85% sensitivity and 75%–85% speciﬁcity [13].
As demonstrated by the study by Hansson and coworkers
as well as other studies [14–20], this goal is achievable with
the CSF biomarkers Aβ42, T-tau, and P-tau even in early
stages.
3. Multicenter Studiesof Diagnostic Accuracy
The results from the above mentioned studies are encour-
aging, but it should be noted that diagnostic biomarkers
generallyperformbetter inhomogenous monocenterstudies
than in more challenging heterogeneous multicenter studies.
So far, only a few large scale multicenter studies of CSF AD
biomarkers have been published. In the DESCRIPA study,
by Visser and coworkers, CSF samples were taken from 193
MCI and (subjective cognitive impairment) SCI patients
and 89 controls at 9 centers in Europe [21]. All samples
were analyzed at one laboratory. The results conﬁrmed
that a CSF AD proﬁle, as deﬁned by Hulstaert et al. [22],
predicted AD in MCI with an odds ratio of 27 (95% CI
1.6–460) in amnestic MCI patients. However, the study was
complicated by the fact that all controls were enrolled at
one center, and CSF sampling procedures diﬀered between
centers. Also, 31% of healthy controls presented a CSF AD
pattern,indicatingalackofspeciﬁcityoftheCSFbiomarkers.
This ﬁnding may seem controversial but is consistent with
a by now large body of literature, showing that around one
third of cognitively normal elderly display AD-like changes
in their brains at autopsy [23], in their CSF [24, 25]o ro n
PET scans imaging amyloid [26–28]. Longitudinal studies
will tell us whether these individuals do have preclinical AD,
or whether silent AD pathology is part of the normal aging
process. Recent studies using repeated cognitive assessments
[29] or functional magnetic resonance imaging measures
of cortical network integrity [30] favor the ﬁrst of the two
scenarios.
Shaw and coworkers have published CSF biomarker
results from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) [31]. The ADNI is a multicenter, longitudinal study,
launched in 2004. In this study, optimal biomarker cut-oﬀs
where established in autopsy conﬁrmed ADNI-independent
AD patients and normal controls, with diagnostic accuracies
ranging from 70% to 87%. The ADNI cohort was recruited
at 56 clinical centers, which potentially could introduce large
center-dependentvariations.Tominimizesuchvariations,all
participating centers followed the ADNI procedure manual.
All samples were analyzed at the ADNI Biomarker Core
laboratory at the University of Pennsylvania. The study
included 196 MCI patients and 37 of these had been
diagnosed with AD at the 12-month follow-up. A majority
(87–89%) of these 37 presented a CSF AD proﬁle at
baseline. This similar to what was seen in patients with
mild AD at baseline (N = 100, 88%–91%). However, as
in the DESCRIPA study, a large proportion (34%–38%)
of cognitively healthy controls (N = 114) had the same
biomarker pattern, again indicating a lack of speciﬁcity in
relation to clinical diagnosis.
In a third multicenter investigation, published in JAMA
in 2009, we enrolled 750 MCI patients, 529 AD patients,
and 304 healthy controls from 12 centers in Europe and
the United States [32]. Four laboratories were involved,
enabling evaluation not only of Intercenter, but also of
interlaboratory diﬀerences, as discussed below. Cut-oﬀsf o r
the combination of Aβ42, T-tau, and P-tau were constructed
in AD patients and controls, with sensitivity 85% in accor-
dance with the above mentioned consensus document. This
yielded 88% speciﬁcity towards healthy controls. In MCI
patients followed for at least 2 years, the sensitivity of the
biomarkers was 83% and the speciﬁcity 72%. The lower
speciﬁcity compared to the monocenter study by Hansson
et al. could partly be explained by the shorter followup,
which makes it hard to verify the benign nature of all
stable MCI cases. However, Intercenter variations may also
have inﬂuenced the results and blurred some eﬀects of the
biomarkers. For the remaining part of this review, we will
focus on such variations, and possible ways of eliminating
them.
4. Intercenter Biomarker Variations
CSF studies on AD patients and controls report diﬀerent
biomarker concentrations, reference ranges, and diagnostic
cut-oﬀs[ 8]. CSF Aβ42 levels in AD patients in some studies
even exceed the levels in controls in other studies. Such
ﬂuctuations make it hard or impossible to compare CSF
biomarkers between centers and studies. These Intercenter
variations come as no surprise. Rather, it is more rule than
exceptionthatanovelclinicalchemicalmeasurementpresent
variations between centers, due to preanalytical or analytical
confoundingfactors.Suchvariationsaretraditionallytackled
by quality control programs, which until recently have been
lacking for CSF dementia markers. For the CSF biomark-
ers Aβ42, T-tau, and P-tau, possible confounding factors
include preanalytical, analytical, and assay factors [33–35].
Preanalytical factors include, for example, usage of diﬀerent
test tubes and diﬀerences in sample handling and storage.
Analytical factors include diﬀerences in pipetting technique
and other laboratory procedures. Finally, important assay
factors are batch-to-batch variations and diﬀerences in
standards and coating of antibodies. A growing number
of laboratories are performing CSF analyses for dementia
diagnostics. To facilitate the use of biomarkers in research
settings and to enable their implementation in clinical
routine, the Intercenter variations must be dealt with. Basic
CSF parameters, including albumin and immunoglobulin
levels, typically have interlaboratory coeﬃcients of variation
(CV) below 10%. This is a reasonable ultimate aim also
for dementia markers. A handful of multicenter studies
have investigated interlaboratory variations in CSF dementia
markers, and we will now summarize the results of these
studies.International Journal of Alzheimer’s Disease 3
5.The FirstInternational
QualityControlSurveys
In 2006, Lewczuk and coworkers published the ﬁrst inter-
national quality control survey of neurochemical dementia
diagnostics [36]. A ventricular CSF sample was collected
from a neurosurgical patient. Fourteen laboratories in Ger-
many, Austria, and Switzerland participated and performed
CSF biomarker measurements according to local routines.
Diﬀerent commercially available ELISAs were used for Aβ
measurement. Three laboratories used a method from The
Genetics Company (Z¨ urich, Switzerland) measuring Aβx-
40 and Aβx-42, with no speciﬁc N-terminal amino acid
capture. Thirteen laboratories used the Innotest (Inno-
genetics, Ghent, Belgium) ELISA for Aβ, which speciﬁcally
measures Aβ1-42. Fourteen laboratories used Innotest for
T-tau, and 11 laboratories used Innotest for P-tau. Inter-
laboratory coeﬃcients of variation ranged from 21% to
38%, with the highest numbers reported for Aβx-42 (38%)
and Aβ1-42 (29%). Most laboratories analyzed samples
in duplicates and the intra-assay imprecision was mostly
low, exceeding 5% only for T-tau (5.3%) and Aβ1-42
(7.5%).
Verwey and coworkers published another quality survey
in 2009 involving 20 laboratories with measurements per-
formedin2004and2008,allowingevaluationoflongitudinal
stability [37]. For this study, large CSF pools with diﬀerent
biomarker patterns were constructed and samples were
distributed to 13 laboratories in 2004 and to 18 laboratories
in 2008. A majority of laboratories used the Innotest ELISA
for T-tau and P-tau, but in the 2008 run some laboratories
had introduced the Luminex method AlzBio3 (Innogenetics,
Ghent, Belgium). ELISA methods generally give higher
values for CSF biomarkers than Luminex methods, but
the methods have equivalent diagnostic accuracy for AD
[38, 39]. Aβ42 was measured with the Innotest ELISA, or
ELISAs from The Genetics Company, Biosource (Invitrogen,
Camarillo, USA) or an in-house assay. Three laboratories
used the AlzBio3 method for Aβ42. Interlaboratory CVs
were high for Aβ42 ELISAs in both 2004 (31%) and
2008 (37%), and somewhat lower when only including
laboratories using the Innotest (30% and 22%, resp.). CVs
were smaller for T-tau (2004: 21%, 2008: 16%) and P-tau
(2004: 13%, 2008: 15%). The AlzBio3 method had CVs
ranging from 14%–22%, but the low number of laboratories
performing this assay makes interpretation diﬃcult. Nine
laboratories participated in both rounds of the survey and
intra-laboratory CVs for these were 25% for Aβ42, 18% for
T-tau and 7% for P-tau.
These two studies show large interlaboratory variations
for Aβ42, and smaller but signiﬁcant variations for T-tau
and P-tau. Since these studies used centrally distributed
control CSF, several preanalytical confounding factors were
eliminated. Remaining possible causes of the variations
include local diﬀerences in analytical routines, machinery
diﬀerences and batch-to-batch variations in analytical kits.
The latter provides a major challenge for kit vendors,
and emphasizes the need to have a robust production of
antibodies, standard solutions, and analytical plates.
6.The SwedishBrainPowerSurvey
In the multicenter study mentioned above, published in
JAMA in 2009, most centers sent their samples to the
Clinical Neurochemistry Laboratory in M¨ olndal for analysis.
However, samples from Amsterdam, Munich, and Kuopio,
Finland were analyzed at local laboratories. The study there-
fore provides information about interlaboratory diﬀerences.
Subset of samples from Amsterdam, Munich and Kuopio
were rerun at the laboratory in M¨ olndal, and values for Aβ42
andT-taufromallthreelocallaboratoriesdiﬀeredmorethan
2CVs from values measured in M¨ olndal, using M¨ olndal CVs
fortheassays(around10%).However,evenforcenterswhere
samples were run at the laboratory in M¨ olndal, considerable
Intercenter variations were seen. Possible sources of these
variations include the preanalytical procedures of subject
selection, lumbar puncture, sample handling, and storage.
Such variations were seen in particular for Aβ42, but to a less
extent also for T-tau and P-tau.
7. The Alzheimer’s Association
QualityControlProgram
The studies outlined above present clear evidence for
Intercenter and interlaboratory variations in CSF biomarker
measurements. This makes it diﬃcult to compare studies,
which may hamper development of CSF biomarkers. With
the rapid development of disease modifying treatment the
AD scientiﬁc community must not lose momentum in
biomarker development. Standardization of collection and
handling of samples is vital for this, such as suggested by,
for example, the German Competence Net Dementias [40].
Accordingly, it was decided at the International Conference
on Alzheimer’s Disease (ICAD) in Vienna in 2009 to start
an international quality control (QC) program for CSF AD
biomarkers. This program is run by the Alzheimer’s Associ-
ation and administrated from the Clinical Neurochemistry
Laboratory in M¨ olndal. The program is open for public,
private, research, clinical, and pharmaceutical laboratories.
Participating laboratories receive a chart with recommended
guidelines for lumbar puncture and sample handling and
storage.InlinewiththeADNIproceduresmanual,theinten-
tion of this chart is to harmonize local routines to eliminate
confounding factors responsible for Intercenter variations.
In a second part of the program, participating laboratories
receive QC CSF samples, constructed in M¨ olndal. These
are analyzed and results are reported to the QC program
coordinator.Theparticipatinglaboratoriesthenreceivefeed-
back on their analysis compared to the other laboratories.
The ﬁrst round of the program has just been completed
and data are being analyzed. The QC program will continue
with multiple rounds each year, enabling the tracking of
longitudinal changes in performance.
8. Conclusions
Multicenter studies have conﬁrmed the high diagnostic
accuracy of CSF biomarkers for AD, even at early stage,4 International Journal of Alzheimer’s Disease
before onset of dementia. In particular, the high diagnostic
sensitivity of CSF biomarkers achieved in the ADNI trial
shows that harmonization of sample collection and han-
dling allows the usage of the biomarkers even in a wide-
spread multicenter setting. This advocates the use of CSF
biomarkers in clinical studies, where they may be used to
enrich trials with MCI patients with incipient AD. However,
to facilitate the development of biomarkers and to enable
their introduction in clinical routine, interlaboratory and
Intercenter diﬀerences should be systematically analyzed.
This is achievable within the Alzheimer’s Association QC
program.
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